Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Chinese Adults with R/R B-precursor ALL
NCT03476239Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2017
- Primary completion
- Aug 2019
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Amgen. Started Oct 2017; status: completed.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03476239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03476239.